|Bid||619.00 x 1200|
|Ask||630.50 x 3000|
|Day's range||622.30 - 632.37|
|52-week range||538.01 - 747.42|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||10.06|
|Earnings date||03 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||685.14|
Regeneron Pharmaceuticals (NASDAQ: REGN) has been a reliable, steadily growing stock over the years, with the top line and profits increasing. Below, I'll look at just how well the stock has performed over the past five years and whether Regeneron is a good buy moving forward. In early August 2017, shares of Regeneron were trading at around $470 per share.
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.